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Impact of Concurrent Genomic 
Alterations Detected by 
Comprehensive Genomic 
Sequencing on Clinical Outcomes 
in East-Asian Patients with EGFR-
Mutated Lung Adenocarcinoma
Seijiro Sato1, Masayuki Nagahashi2, Terumoto Koike1, Hiroshi Ichikawa2, Yoshifumi 
Shimada2, Satoshi Watanabe3, Toshiaki Kikuchi3, Kazuki Takada  4, Ryota Nakanishi4,  
Eiji Oki4, Tatsuro Okamoto4, Kouhei Akazawa5, Stephen Lyle6, Yiwei Ling7, Kazuaki Takabe8,9, 
Shujiro Okuda  7, Toshifumi Wakai2 & Masanori Tsuchida1
Next-generation sequencing (NGS) has enabled comprehensive detection of genomic alterations in 
lung cancer. Ethnic differences may play a critical role in the efficacy of targeted therapies. The aim 
of this study was to identify and compare genomic alterations of lung adenocarcinoma between 
Japanese patients and the Cancer Genome Atlas (TCGA), which majority of patients are from the 
US. We also aimed to examine prognostic impact of additional genomic alterations in patients 
harboring EGFR mutations. Genomic alterations were determined in Japanese patients with lung 
adenocarcinoma (N = 100) using NGS-based sequencing of 415 known cancer genes, and correlated 
with clinical outcome. EGFR active mutations, i.e., those involving exon 19 deletion or an L858R point 
mutation, were seen in 43% of patients. Some differences in driver gene mutation prevalence were 
observed between the Japanese cohort described in the present study and the TCGA. Japanese cohort 
had significantly more genomic alterations in cell cycle pathway, i.e., CDKN2B and RB1 than TCGA. 
Concurrent mutations, in genes such as CDKN2B or RB1, were associated with worse clinical outcome 
in patients with EGFR active mutations. Our data support the utility of comprehensive sequencing to 
detect concurrent genomic variations that may affect clinical outcomes in this disease.
Lung tumors are the most prevalent type of cancer and are one of the leading causes of cancer-related death 
worldwide1. The discovery that epidermal growth factor receptor (EGFR) mutation is a predictor of clinical 
response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) has dramatically changed the therapeutic approach 
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to non-small cell lung cancer (NSCLC)2,3. In addition to EGFR, several oncogenic drivers such as anaplastic lym-
phoma kinase (ALK), ROS proto-oncogene 1, receptor tyrosine kinase (ROS1), and ret proto-oncogene (RET) 
have been as identified as molecular targets in this disease4,5. The effectiveness of molecularly targeted therapies, 
and advances in technologies for the detection of genomic alterations in tumors, have driven an increasing inter-
est in such precision medicine approaches.
The advent of next-generation sequencing (NGS) has enabled the comprehensive detection of genomic alter-
ations. Utilizing NGS technology, the Cancer Genome Atlas (TCGA) consortium has reported the molecular 
profiling of 230 lung adenocarcinoma cases, and the detection of mutations in genes such as neurofibromatosis 
type 1 (NF1), MET proto-oncogene, receptor tyrosine kinase (MET), and erb-b2 receptor tyrosine kinase 2 gene 
(ERBB2)6. Although the TCGA represents one of the largest cohorts of NSCLC patients6,7, its limitation is that 
minor ethnicities are not well represented because samples are derived solely from USA-based institutions. It is 
well known that cancers differ biologically between ethnicities, but to date, genomic data from east-Asian popu-
lations have been scarce8.
We hypothesized that sequencing a panel of cancer-associated genes using NGS technology would identify 
essentially all actionable genomic driver mutations in lung adenocarcinoma, regardless of ethnic and geographi-
cal background. Moreover, we hypothesized that comprehensive sequencing would identify not only the known 
actionable driver mutations, such as those affecting EGFR, but also other important gene alterations that may 
impact clinical outcome. To test these hypotheses, we assessed the genomic profile of a Japanese cohort of lung 
adenocarcinoma patients using NGS-based sequencing of 415 genes, and compared the results with data from 
TCGA. Finally, it has been reported that the EGFR-mutated patient ratio of east-Asian origin is high compared 
with Westerners6,9, so we evaluated the clinical benefit of this approach by examining the association between 
concurrent genomic alterations in patients harboring EGFR active mutations and their subsequent therapeutic 
outcome.
Results
Patient characteristics. The demographic data for the 100 patients included in this study are shown in 
Table 1. The median follow-up period after surgery was 32.6 months (range 6.4–104.8). In regard to smoking 
status, 62 patients identified as never having smoked or as light smokers (pack-years, or PY < 30), and 38 patients 
were heavy smokers (PY ≥ 30). Overall, the median mutation burden (number of rare SNPs) was 13.5 (range 
5–33) and the median number of identified genomic alterations was four (range 1–19), with 98% of patients 
having one or more actionable mutations, defined as genomic alterations that are either associated with targeted 
therapy that is FDA/PMDA- approved or would qualify the patient for a clinical trial testing a targeted therapy.
The frequency of genomic alterations. Tumors were sequenced with a median coverage of 500× , and 
a total of 281 individual genomic alterations were identified. EGFR was the most commonly mutated gene (48% 
of patients, n = 48/100), followed by tumor protein p53 gene (TP53) (40%) and cyclin-dependent kinase inhib-
itor 2B (CDKN2B) (32%) as shown in Table 2. EGFR active mutations, i.e., those involving exon 19 deletion or 
an L858R point mutation, were detected in 43 patients, with six patients showing more than one mutation in 
EGFR (see Supplementary Tables S1 and S2). Compared with data from TCGA6,7, there were significantly more 
genomic alterations in AT-rich interactive domain-containing protein 1A (ARID1A), EGFR, cyclin-dependent 
kinase inhibitor 1B (CDKN1B), cyclin-dependent kinase inhibitor 2A (CDKN2A), retinoblastoma 1 gene (RB1), 
phosphatase and tensin homolog (PTEN), activin receptor type 2 (ACVR2A), and F-box/WD repeat-containing 
protein 7 (FBXW7) (all p < 0.01) and significantly less genomic alterations in erb-b4 receptor tyrosine kinase 4 
gene (ERBB4), Kirsten rat sarcoma viral oncogene homolog gene (KRAS), and Kelch-like ECH-associated protein 
1 (KEAP1) (p = 0.01, p < 0.01, and p < 0.01, respectively) among our Japanese patients (Table 2).
Overall impact of genomic alterations on clinical outcome in lung adenocarcinoma. We next 
assessed the impact of each genomic alteration on the clinical outcomes of patients in our cohort (Table 3). 
Univariate analysis indicated that patients with EGFR active mutations had significantly longer disease-free 
survival (DFS) than patients without these mutations (p = 0.041). Conversely, patients with TP53 mutation or 
CDKN2B mutation had significantly shorter DFS than patients without those mutations. In multivariate analy-
sis, TP53 mutation and CDKN2B mutation remained independent predictors of DFS (p = 0.037 and p = 0.002, 
Factor Category N = 100
Age (Years)
Median 67
Range 36–86
Gender (N)
Male 67
Female 33
Smoking (N)
PY < 30 62
PY ≥ 30 38
Stage (N)
I 31
II 24
III 39
IV 6
Table 1. Patient demographics. N, number; PY, pack-years.
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respectively), but EGFR active mutation did not (p = 0.050). In regards to overall survival (OS), however, uni-
variate analysis indicated that patients with any EGFR mutation, not just those with EGFR active mutation, had 
significantly longer OS (p = 0.020 and p = 0.027, respectively).
EGFR genomic alterations and clinical outcome. We next examined the clinical outcome of patients with 
EGFR mutations in more detail. The majority of the patients with EGFR mutations (84%) identified as either having 
never smoked or as light smokers (see Supplementary Table S1). In terms of clinical outcome, the 48 patients with 
EGFR mutation showed a trend towards longer DFS and a significantly longer OS, than those without EGFR muta-
tion (Fig. 1A,B; log-rank test, p = 0.069 and p = 0.015, respectively). When only the 43 patients with EGFR active 
mutations were considered, both DFS and OS were found to be significantly longer than for patients with wildtype 
EGFR or EGFR non-active mutations (Fig. 1C,D; log-rank test, p = 0.038 and p = 0.021, respectively).
Frequency (%) Frequency (%)
TCGA This study TCGA This study
(N = 216) (N = 100) (N = 216) (N = 100)
Transcription factor/regulator
2.6 0.0 GATA3 MAPK signaling 26.3 12.0 KRAS
0.9 0.0 EP300 11.8 2.0 NF1
4.0 0.0 TAF1 1.8 0.0 MAP3K1
0.4 0.0 RUNX1 6.6 5.0 BRAF
3.5 1.0 WT1 1.8 0.0 NRAS
0.4 0.0 FOXA1 1.3 0.0 MAP2K4
0.4 0.0 CBFB PI(3)K signaling 4.4 6.0 PIK3CA
1.3 0.0 SOX9 2.2 17.0 PTEN
Histone modifier 6.1 17.0 ARID1A 1.3 4.0 PIK3R1
1.8 4.0 PBRM1 11.4 0.0 TLR4
7.9 2.0 SETD2 5.3 0.0 PIK3CG
4.8 1.0 KDM5C 0.0 2.0 AKT1
0.9 0.0 KDM6A TGF-β signaling 3.1 4.0 SMAD4
1.3 0.0 ASXL1 0.9 4.0 TGFBR2
2.2 0.0 EZH2 2.2 1.0 ACVR1B
Genome integrity 51.8 40 TP53 0.9 1.0 SMAD2
7.9 3.0 ATM 0.9 12.0 ACVR2A
6.1 2.0 ATRX Wnt/β-catenin 9.2 16.0 APC
5.7 10.0 BRCA2 3.5 5.0 CTNNB1
5.7 0.0 ATR 0.9 0.0 AXIN2
2.6 0.0 STAG2 Proteolysis 1.3 13.0 FBXW7
1.3 1.0 BAP1 17.1 2.0 KEAP1
3.5 NA BRCA1 0.4 0.0 SPOP
1.3 0.0 ERCC2 Splicing 2.2 0.0 SF3B1
RTK signaling 11.4 48.0 EGFR HIPPO signaling 1.3 2.0 CDH1
4.0 1.0 FLT3 DNA methylation 4.0 0.0 DNMT3A
8.8 2.0 EPHA3 3.1 0.0 TET2
7.5 1.0 ERBB4 Metabolism 0.9 0.0 IDH1
6.6 2.0 PDGFRA 0.4 1.0 IDH2
9.7 0.0 EPHB6 NFE2L 2.2 2.0 NFE2L2
3.1 0.0 FGFR2 Protein phosphatase 4.6 0.0 PPP2R1A
1.8 3.0 KIT TOR signaling 7.5 1.0 MTOR
0.4 2.0 FGFR3 8.8 15.0 STK11
Cell cycle 6.6 17.0 CDKN2A Other 3.1 0.0 NOTCH1
5.3 22.0 RB1 5.3 0.0 USP9X
3.1 1.0 CDK12 0.9 0.0 NPM1
1.8 19.0 CDKN1B 10.5 1.0 HGF
0.9 1.0 CCND1 1.8 0.0 AR
0.4 0.0 CDKN1A
0.0 0.0 CDKN2C
NA 32.0 CDKN2B
Table 2. Frequency of Gene Alterations in Each Pathway. Bolded entries represent those genes for which the 
frequency of alteration was significantly different between TCGA and the present study; N, number; NA, not 
available.
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Concurrent genomic alterations in patients with EGFR active mutation. Subsequently, we assessed 
the incidence of concurrent genomic alteration in the 43 patients with EGFR active mutation. The most frequent 
concurrent genomic alterations in these patients were CDKN2B (37% of patients), TP53 (28%), CDKN2A (23%), 
CDKN1B (21%), ARID1A (19%), RB1 (16%), and serine/threonine kinase 11 (STK11) (16%) (Fig. 2). In agree-
ment with previous reports10, there were no concurrent genomic alterations in KRAS, ALK, ROS1, RET, B-Raf 
proto-oncogene (BRAF) (V600E) or MET. We also examined differences in the pattern of concurrent genomic 
alteration in patients with EGFR active mutation vs. those with either EGFR wildtype or EGFR non-active muta-
tion. This analysis revealed that patients with EGFR active mutation carried fewer TP53 mutations and PTEN 
mutations than the others (p = 0.026 and p = 0.018, respectively; see Supplementary Table S3). We also compared 
the pattern of concurrent genomic alteration in patients with EGFR exon19 deletion and those with EGFR L858R 
mutation (Fig. 2); however, no significant differences were found between the two groups.
Impact of concurrent genomic alterations on clinical outcomes in patients with EGFR active 
mutation. To assess the impact of concurrent genomic alterations on clinical outcomes in patients with EGFR 
active mutations, survival of these patients was compared to patients with wildtype EGFR or EGFR non-active 
mutations. Univariate analysis revealed that patients with CDKN2B mutation had significantly shorter DFS than 
those without CDKN2B mutation (p = 0.001, Table 4), while patients with RB1 mutation had significantly shorter 
OS than those without RB1 mutation (p = 0.035, see Supplementary Table S4). These findings suggest that con-
current genetic alterations affect clinical outcomes in patients with EGFR active mutations.
We also examined the impact of concurrent genomic alterations on clinical outcomes in patients with wild-
type EGFR or non-active EGFR mutations. In this analysis, patients with STK11 mutation were found to have 
significantly shorter DFS (p = 0.006, Table 5) and OS (p = 0.046, see Supplementary Table S5) than those without 
Genes Category N = 100
5-year 
DFS (%)
Univariate Analysis Multivariate Analysis 5-year 
OS (%)
Univariate Analysis
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
EGFR (All)
WT 52 35.5 55.0
MUT 48 33.4 0.610 (0.356–1.045) 0.072 77.3 0.356 (0.149–0.847) 0.020
EGFR (active)a
Otherb 57 31.7 Referencec 55.6
MUT 43 38.6 0.559 (0.320–0.977) 0.041 0.607 (0.335–1.100) 0.050 79.1 0.357 (0.143–0.890) 0.027
TP53
WT 60 41.5 Reference 76.9
MUT 40 28.9 1.795 (1.056–3.051) 0.031 1.727 (1.003–2.975) 0.037 52.4 2.042 (0.936–4.458) 0.073
CDKN2B
WT 68 51.6 Reference 62.9
MUT 32 7.1 2.151 (1.253–3.694) 0.005 2.391 (1.376–4.155) 0.002 70.9 0.761 (0.317–1.823) 0.540
RB1
WT 79 36.0 65.4
MUT 21 34.3 1.459 (0.783–2.722) 0.234 66.2 1.208 (0.485–3.011) 0.685
CDKN1B
WT 81 33.8 61.8
MUT 19 40.6 0.948 (0.487–1.844) 0.875 75.9 0.522 (0.179–1.524) 0.234
CDKN2A
WT 83 44.4 64.7
MUT 17 9.9 1.263 (0.665–2.401) 0.476 64.2 1.071 (0.401–2.860) 0.892
PTEN
WT 83 33.3 63.6
MUT 17 47.1 1.092 (0.533–2.236) 0.810 72.1 0.880 (0.303–2.559) 0.815
ARID1A
WT 83 30.9 63.6
MUT 17 58.8 0.811 (0.382–1.722) 0.585 71.7 1.196 (0.449–3.185) 0.721
APC
WT 84 37.9 63.8
MUT 16 29.5 1.061 (0.533–2.110) 0.866 65.6 1.295 (0.516–3.254) 0.582
STK11
WT 85 39.5 67.2
MUT 15 18.8 1.707 (0.858–3.395) 0.128 46.7 1.793 (0.672–4.782) 0.243
FBXW7
WT 87 30.3 63.6
MUT 13 65.9 0.511 (0.203–1.288) 0.155 72.5 1.131 (0.386–3.315) 0.822
KRAS
WT 88 37.0 71.9
MUT 12 25.0 1.947 (0.950–3.992) 0.069 44.4 2.277 (0.910–5.696) 0.078
ACVR2A
WT 88 33.7 63.2
MUT 12 56.3 0.493 (0.178–1.366) 0.174 83.3 0.631 (0.149–2.680) 0.533
Table 3. Univariate and Multivariate Survival Analysis of DFS and OS in All Patients. Note: Only those genes 
mutated in more than 12 patients were analyzed. aActive EGFR mutation refers to exon19 deletion or L858R 
point mutations. bOther refers to patients with wildtype EGFR or non-active EGFR mutations. cMultivariate 
analysis was performed for the EGFR active mutation group, since the data for those with active mutations 
and those with any EGFR mutation overlapped considerably. DFS, disease-free survival; OS, overall survival; 
N, number; HR, hazard ratio; CI, confidence interval; WT, wildtype; Mut, mutated; Bold values are those with 
statistical significance of p < 0.05.
www.nature.com/scientificreports/
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STK11 mutations. Of note, neither CDKN2B nor RB1 were associated with DFS or OS in the patients with wild-
type EGFR or non-active EGFR mutations.
Clinical outcomes for patients receiving EGFR-TKI therapy. In total, 14 patients received 
first-generation EGFR-TKI therapy, i.e., gefitinib or erlotinib, for recurrence; however, in one patient an osteo-
sclerotic metastasis in the fourth thoracic vertebra was detected by bone scintigraphy; that lesion was determined 
to be non-measurable by the RECIST v1.1 guidelines11, and thus the patient was excluded from the analysis. One 
patient received EGFR-TKI therapy, however, the patient was excluded from this study due to serious adverse 
event happened early after the administration of EGFR-TKI. The others did not develop recurrence or metastatic 
disease except two: one patient had a recurrence with brain metastasis and received radiation therapy; one patient 
developed recurrence but had not started treatment yet. Of the remaining 12 patients, two were designated as 
non-responders (Fig. 3). Interestingly, the number of genomic alterations in the two non-responders was found 
to be the highest of any of the patients who received EGFR-TKI treatment (Fig. 3).
To gain a clearer understanding of factors that may have contributed to the poor clinical response of these 
two patients, we examined their medical records in more detail. Briefly, Case 1 initially received right middle 
lobectomy with lymph node dissection. Two months following surgery, chest CT revealed the presence of medi-
astinal lymph nodes and supraclavicular lymph node metastases. After the failure of concurrent platinum-based 
chemotherapy and thoracic radiotherapy, new multiple small (<10 mm) brain and osteosclerotic bone metastases 
were found to have developed. At this point the patient received EGFR-TKI therapy; however, multiple bone 
metastases were detected approximately 2 months later. Case 2 underwent right lower lobectomy with lymph 
node dissection. Seven months after surgery, bone scintigraphy revealed osteosclerotic metastases to the cervi-
cal vertebrae. Following irradiation of the cervical vertebrae lesion the patient received EGFR-TKI therapy, but 
malignant pleural effusion and lymphangiosis carcinomatosa developed approximately 1 month later.
Notably, we investigated the association between the number of genomic alterations and progression-free 
survival (PFS) of the patients with EGFR-TKI therapy. We found the patients with 4 or more genomic alterations 
had significantly poorer PFS than those with less than 4 (p = 0.006) (Supplementary Fig. S6).
Figure 1. Effect of EGFR mutation status on patient survival. Postoperative disease-free survival (A) and overall 
survival (B) curves for patients with or without any type of EGFR mutation, and disease-free survival (C) and 
overall survival (D) curves for patients with or without EGFR active mutations (i.e., exon19 deletion or L858R 
point mutation). ‘Other’ indicates patients with either wildtype EGFR or an EGFR non-active mutation.
www.nature.com/scientificreports/
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Discussion
NGS technologies enable us to identify not only potentially targetable driver mutations but also other impor-
tant genomic alterations that are associated with clinical outcome. In the present study, we identified actiona-
ble genomic driver mutations in 98% of patients in a Japanese lung adenocarcinoma cohort by comprehensive 
NGS-based sequencing of a panel of 415 genes with relevance for cancer, with an average of 500× depth. In 
contrast, TCGA performed whole-exome sequencing on tumor, with a mean coverage of 97.6× depth. Although 
the sequence techniques had been not the same, of note, there were differences in the observed prevalence for 
several driver gene mutations between the Japanese and TCGA cohorts, consistent with previous reports12,13. 
Furthermore, we found that concurrent mutations, in genes such as CDKN2B and RB1, may impact the survival 
of patients with EGFR mutations.
The CDKN2B gene lies adjacent to the tumor suppressor gene CDKN2A in a genomic region that is frequently 
mutated and/or deleted in various tumor types. CDKN2B encodes a cyclin-dependent kinase (CDK) inhibitor 
known as p15Ink4b, which forms a complex with CDK4 or CDK6 and prevents their ability inactivate the RB1 
gene product (Rb) and other Rb-family proteins during the G1 phase of the cell cycle. The p15Ink4b protein thus 
functions as a cell growth regulator that inhibits cell cycle progression14. Zhao et al. reported that CDKN2B loss 
is associated with poor overall survival of patients with lung squamous cell carcinoma15, and in NSCLC patients, 
loss of chromosome 9p (encompassing the 9p21.3 locus where CDKN2A and CDKN2B are located) has also 
been associated with poor survival outcome16,17. Moreover, CDKN2A and CDKN2B are known to be frequently 
inactivated by allelic loss and promotor methylation in NSCLC, resulting in the deregulation of cell proliferation 
through the loss of G1 arrest control18.
Like CDKN2B, the RB1 gene is also an important regulator of cell cycle progression. Together with other Rb 
family members (such as p107 and p130), Rb is phosphorylated by CDK4/6 and other cyclin-CDK complexes, 
inducing the release of transcription factors of the E2F family and the consequent transcription of genes required 
for S-phase entry19. Molecular alterations involving the CyclinD1-CDK4/6-Rb pathway occur in a variety of 
malignancies such as breast cancer20, prostate cancer21, and osteosarcoma22, and have been associated with poor 
prognosis. In regard to lung cancer, recent whole-genome sequencing has revealed that the RB1 gene is altered in 
almost all cases of small cell carcinoma23. It remains premature to determine the clinical outcome on this popu-
lation due to the small sample size of this study. However, considering that the CyclinD1-CDK4/6-Rb pathway 
is downstream of the EGFR signaling pathway, it is likely that this cell cycle pathway, which involves CDKN2B 
and RB1, plays an important role in lung cancer progression and/or therapeutic resistance in patients with EGFR 
active mutation.
A previous study has reported that lung adenocarcinoma patients with relapse have a significantly larger pro-
portion of private non-trunk mutations in their primary tumor than those without relapse, indicating not only 
Figure 2. Concurrent genetic alterations among patients with EGFR active mutation. Percentages indicate the 
frequency of each mutation in these 43 patients, with the heatmap indicating the presence or absence of the 
variation in individuals. Green cells, SNPs; black cells, stop-gain mutations; red cells, gene amplification; blue 
cells, genomic loss.
www.nature.com/scientificreports/
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that subclonal mutations are crucial for tumor progression, but that they increase postoperative risk of relapse24. 
Notably, the two lung adenocarcinoma patients in our cohort that carried the highest number of oncogenic gene 
alterations, showed no clinical response to EGFR-TKI therapy. This observation supports the concept that it is not 
just major driver mutations that affect therapeutic response and clinical outcome, and highlights the importance 
of conducting comprehensive genome sequencing in patients with lung adenocarcinoma.
In regard to the EGFR gene, we identified differences in DFS and OS between patients with EGFR active muta-
tion and those with wildtype EGFR or non-active EGFR mutations. Although the prognostic impact of EGFR 
mutation in lung adenocarcinoma remains controversial, several retrospective studies have reported that patients 
with EGFR mutation survived for longer periods than those without mutations, irrespective of therapy25,26. Such 
results may in part be a reflection of cohort composition in regard to gender and smoker status, with several 
investigators having reported that among patients with NSCLC, those that have never smoked have a better OS 
than smokers24,27.
It is important to point out that the current study has some limitations. Firstly, this is a retrospective study 
with a relatively small number of patients. Secondly, we noted an imbalance between the proportion of Stage 
I/II and Stage III/IV surgically resected cases in comparison with reported data for other Japanese cohorts28. 
Since only patients from whom sufficient amounts of tumor DNA could be extracted from FFPE specimens were 
included in this study, the proportion of advanced stage cases in our study was understandably higher. Third, 
when assessing the impact of each genomic alteration on DFS and OS, we did not perform multiple testing cor-
rection. This is because we analyzed only about 10 genomic alterations on survival and the sample size of this 
study was limited due to the cost of NGS analyses. However, to our knowledge, the present study represents the 
largest cohort of Japanese lung adenocarcinoma patients to have been genomically characterized using a com-
prehensive gene panel, and thus contributes substantially to our understanding of the clinical progression of lung 
adenocarcinoma in this population.
In conclusion, using an NGS sequencing approach we have identified actionable genomic driver mutations 
in 98% of Japanese lung adenocarcinoma patients, and discovered that the mutation frequencies of several key 
genes in this population appear to differ from those described in the TCGA database. Notably, concurrent loss 
of CDKN2B or RB1 was associated with poor prognosis in patients with EGFR active mutation. In addition, our 
data indicate that lung adenocarcinoma patients with high numbers of oncogenic gene alterations may show 
the worst responses to EGFR-TKI targeted therapy. Although further studies are needed to verify these find-
ings, our data improve our understanding of the relationship between genomic alteration and prognosis in lung 
adenocarcinoma.
Material and Methods
Patients and tissues. This study was approved by the Institutional Review Boards of Niigata University, and 
Kyusyu University Hospital. At Niigata University, patients were recruited from January 2008 to December 2014, 
and at Kyushu University from October 2013 to August 2015. All methods were performed in accordance with the 
Genes Category N = 43 5-year DFS (%)
Univariate Analysis
HR (95% CI) p-value
CDKN2B
WT 27 51.6
MUT 16 7.1 5.618 (1.995–15.827) 0.001
CDKN2A
WT 33 54.7
MUT 10 14.6 1.887 (0.728–4.892) 0.191
CDKN1B
WT 34 28.7
MUT 9 62.2 0.435 (0.123–1.540) 0.197
TP53
WT 31 47.0
MUT 12 31.3 2.495 (0.956–6.510) 0.062
STK11
WT 36 44.7
MUT 7 33.3 0.864 (0.246–3.035) 0.820
RB1
WT 36 41.1
MUT 7 28.6 1.875 (0.601–5.848) 0.279
ARID1A
WT 35 24.1
MUT 8 100 0.136 (0.030–2.492) 0.056
FBXW7
WT 37 30.3
MUT 6 62.5 0.715 (0.196–2.621) 0.613
EGFR*
WT 37 36.5
MUT 6 44.4 1.737 (0.566–5.329) 0.334
Table 4. Univariate Analysis of DFS in Patients with EGFR Active Mutations. Note: Only genes mutated in 
more than six patients were analyzed. *Refers to EGFR non-active mutations, i.e., excluding Exon19 deletion 
and L858R. DFS, disease-free survival; N, number; HR, hazard ratio; CI, confidence interval; PY, pack-year; 
WT, wild type; MUT, mutated; Bold values are those with statistical significance of p < 0.05.
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relevant guidelines and regulations, and written informed consent was obtained from all patients. Patients were 
selected using the following three criteria: firstly, a tumor content of >20% based on pathological review of hema-
toxylin and eosin (H&E) stained slides. Secondly, radiological confirmation of lung adenocarcinoma with a con-
solidation/tumor ratio (C/T ratio) >0.5 using thin-section computed tomography (CT). Thirdly, the successful 
extraction of ≥150 ng DNA from each sample. One hundred patients who underwent surgery for primary lung 
adenocarcinoma were finally enrolled into the study, with all clinicopathology data, including smoking history, 
being retrieved from medical records. Six patients with Stage IV disease were included in our cohort. Preoperative 
work up revealed no metastasis and their diseases were clinically diagnosed as Stage I in 3 patients, Stage II in 2 
patients, and Stage III in one preoperatively, however, they were found to have dissemination to visceral pleura by 
postoperative pathological examination (Table 1).
Sequencing library preparation. Formalin-fixed, paraffin embedded (FFPE) cancer tissue from surgical 
specimens was used for analysis. An independent pathologist evaluated the tumor content using H&E slides. 
Where applicable, unstained slides were macro-dissected to enrich for tumor content and genomic DNA was 
extracted using the BiOstic FFPE Tissue DNA Isolation Kit (Mo Bio Laboratories, Inc; Carlsbad, CA). Sample 
preparation, genomic sequencing and subsequent analyses were all performed in a CLIA/CAP-accredited labo-
ratory (KEW Inc.; Cambridge, MA).
Comprehensive genomic sequencing. FFPE genomic DNA (150 ng) was converted into libraries and 
enriched for a 415 gene panel with CANCERPLEX (KEW Inc.; Cambridge, MA). CANCERPLEX is a clini-
cally validated gene panel enriched for the coding regions and selected introns of 415 genes with known rele-
vance for cancer. Sequencing was performed on the Illumina MiSeq and NextSeq platforms with an average of 
500× sequencing depth. Genomic data were then processed through a proprietary bioinformatics platform and 
knowledge base to identify multiple classes of genomic abnormalities, including single-nucleotide substitutions 
(SNPs), small insertions/deletions (indels), copy number variations (CNVs), and translocations in ALK, RET, 
and ROS1. A threshold of 10% allelic fraction was used for SNPs and indels, and thresholds of >2.5-fold (gains) 
and 0.5-fold (losses) were used for CNVs. To assess the somatic status of mutations in the absence of constitutive 
samples, we employed a filtering strategy similar to one recently published, but with minor differences29,30. Based 
on both published evidence and our own experience, this approach allows the correct discrimination between 
germline and somatic variants in >99% of cases. Mutation burden was determined by the number of nonsyn-
onymous SNPs present in the tumor that had population frequencies of <1% in dbSNP and the 1000 genomes 
databases. Actionable mutations were defined as known oncogenic alterations in key driver genes that are asso-
ciated with response to approved targeted therapies (e.g., exon 19 deletions in EGFR). The number of genomic 
alterations was calculated in the context of the total number of genes represented on the CANCERPLEX panel. 
EGFR active mutations were defined as those involving EGFR exon 19 deletion or an L858R point mutation.
Genes Category N = 57 5-yr DFS (%)
Univariate Analysis
HR (95% CI) p-value
TP53
WT 29 34.4
MUT 28 28.3 1.386 (0.720–2.668) 0.329
CDKN2B
WT 41 38.9
MUT 16 0.0 1.343 (0.667–2.706) 0.409
RB1
WT 43 30.0
MUT 14 12.8 1.304 (0.612–2.781) 0.491
PTEN
WT 43 28.3
MUT 14 35.7 1.185 (0.555–2.530) 0.662
KRAS
WT 45 33.1
MUT 12 25.0 1.571 (0.737–3.348) 0.242
APC
WT 45 32.1
MUT 12 35.0 0.762 (0.331–1.752) 0.522
CDKN1B
WT 47 33.4
MUT 10 20.0 1.537 (0.699–3.380) 0.285
ARID1A
WT 48 32.4
MUT 9 22.2 2.004 (0.871–4.614) 0.102
STK11
WT 49 35.3
MUT 8 12.5 3.268 (1.402–7.618) 0.006
BRCA2
WT 49 27.7
MUT 8 50.0 0.603 (0.213–1.711) 0.342
Table 5. Univariate Analysis of DFS in Patients with Wildtype EGFR or Non-active EGFR Mutations. Note: 
Only genes mutated in more than eight patients were analyzed. DFS, disease-free survival; N, number; HR, 
hazard ratio; CI, confidence interval; WT, wildtype; MUT, mutated; Bold values are those with statistical 
significance of p < 0.05.
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Statistical analysis. Associations between each genotype and clinical characteristics were analyzed using 
two-tailed Student’s t tests and Fisher’s exact tests. Disease-free survival (DFS) was defined as the time from 
surgery to documented clinical progression or death. Overall survival (OS) was defined as the time from surgery 
until death. Progression-free survival (PFS) was defined as the time from the treatment to disease progression 
or death from any cause. As for PFS, we have established the cutoff value (4 or more vs. less than 4), which was 
based on the median number of identified genomic alterations in all patients. Survival curves were constructed 
using the Kaplan-Meier method, with statistical significance determined by log-rank test. Univariate and multi-
variate Cox proportional hazards models were developed to determine which factors had a significant impact on 
survival and to assess independent prognostic significance. All factors that attained a significance level of p < 0.05 
in univariate analysis were included in the multivariate analysis. Statistical analysis was performed using SPSS 
for Windows Version 23.0 (SPSS, Inc., Chicago, IL, USA), with p < 0.05 being considered statistically significant.
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